Articles tagged with Schizophrenia
Researchers found that a balance between dopamine D2 receptors and RGS is crucial for normal long-term memory formation. An imbalance in these molecules is thought to contribute to the development of schizophrenia and dystonia.
Scientists have developed an improved technique to trace brain connections between neurons in zebrafish using vesicular stomatitis virus (VSV), enabling the visualization of connected neurons up to five days after infection. This breakthrough could provide insights into brain network connectivity repair after injury or disease.
Researchers investigated whether allergic diseases cause mental health conditions, finding little evidence of a causal relationship. The study used Mendelian Randomisation to identify genetic variants linked to allergies and mental health, but found no associations between the two.
A computational framework will be developed to characterize how genetic variants work at the cellular level in psychiatric diseases like schizophrenia and bipolar disorder. The framework aims to integrate data from live and postmortem samples, humans and mice, to accurately pinpoint which mutations result in disorders.
The American Psychiatric Association journals feature research on the mental health of community college students, diabetes, depression, and schizophrenia treatment. The findings extend and validate previous studies relevant to clinical psychiatry.
A new study found that schizophrenia is associated with a loss of excitation but an increase in inhibition, resulting in hallucinations. The researchers used EEG data from 107 participants to demonstrate decreased synaptic gain, which may guide pharmacological and neurostimulation treatments.
A common blood test could identify patients with schizophrenia at high risk for cardiovascular disease, enabling early intervention. Elevated white blood cell counts are suspected to be a signal, and a large-scale analysis of over 20,000 patients will examine its associations.
A Bristol-led research team has identified specific receptors for the neurotransmitter acetylcholine that re-route information flowing through memory circuits in the hippocampus. The discovery holds promise for developing new, safer treatments for conditions like Alzheimer's disease and schizophrenia.
A Mount Sinai study found that polygenic risk scores were no better at predicting worsening symptoms than written reports in schizophrenia patients. The results raise questions about the use of polygenic risk scores in real-world situations, suggesting a doctor's report may be an untapped source of predictive information.
A study of 277 drug-naive adolescents found a link between fingertip advanced glycation end products and the trajectory of psychotic symptoms. Baseline levels of these compounds predicted the risk of persistent psychotic symptoms, suggesting their involvement in the pathophysiology of early psychosis.
Researchers from Okayama University conducted a randomized trial to assess the benefits of interventions for early cancer screening in patients with schizophrenia. The study found that 47.1% of counseled patients underwent colorectal cancer screening, compared to 11.8% of those receiving only usual treatment.
A study found that plasma pentosidine levels, a marker of advanced glycation end products, were significantly associated with impaired processing speed in schizophrenia patients. The results suggest that reducing AGEs may contribute to improving cognitive function and promoting recovery in patients with schizophrenia.
Researchers at Baylor College of Medicine developed a machine learning algorithm that analyzes DNA methylation patterns in blood samples to identify individuals with schizophrenia. The study achieved an 80% accuracy rate and identified epigenetic markers that differ between people diagnosed with the condition and those without it.
Researchers have discovered the amygdala's role in pre-attentive mechanisms, shedding light on its connection to schizophrenia and other disorders. The study found that activating brain stem inhibitory neurons via the amygdala is crucial for startle inhibition.
Scientists have discovered a protein biomarker in blood that could help diagnose schizophrenia at an early age. The study found high levels of active CRMP2 protein, which is uniquely imbalanced in people diagnosed with the condition.
Researchers at the University of Otago have created a new animal model that can accurately simulate psychosis in rats. This breakthrough finding opens up new possibilities for understanding brain mechanisms and developing more effective treatments for schizophrenia.
Researchers found impaired neurotransmitter release and synaptic signaling in human-derived neurons from patients with schizophrenia and a rare genetic mutation. This discovery provides insight into the cellular pathways perturbed in schizophrenia and offers a lead for studying this biology.
A study by CU researchers found that choline deficiency in Black pregnant women is linked to increased risk of developmental and behavioral issues in their children's later lives. The research also highlights healthcare disparities in caring for Black mothers and their children in the US.
Researchers have found 22 lipids linked to lower symptom improvement in people with schizophrenia during treatment. The study's findings suggest a complex interplay between metabolic abnormalities and psychiatric health, highlighting the potential of lipidomics as a promising field for new discoveries.
Research found that mice with impaired methylglyoxal detoxification systems exhibited schizophrenia-like behavioral abnormalities, including social interaction and cognitive memory impairments. Low levels of vitamin B6 were also observed in mice and patients with schizophrenia.
Neuroscientists at UCL have identified abnormalities in the way memories are 'replayed' in the brains of people with schizophrenia. The study found that individuals with schizophrenia were less able to build a structure of the task, with impaired neural replay linked to their symptoms.
Researchers found significant correlations between brain capillary curvature and neurite thickness radius in schizophrenia patients, but not between capillary diameter and neurite thickness. The study suggests neurovascular abnormalities contribute to schizophrenia.
A recent study has found a possible link between prostate cancer and schizophrenia, with certain gene polymorphisms correlated to disease prognosis. Polymorphisms in genes controlling neurotransmitter metabolism were studied in patients with prostate cancer, revealing a potential protective effect against schizophrenia-like symptoms.
A study using protein mapping reveals that abnormal glutamate levels in the brains of schizophrenic patients can lead to oxidative stress and apoptosis in neurons, while oligodendrocytes display different responses. This knowledge may contribute to the development of more targeted treatments for schizophrenia.
A new study from Columbia University found that young adults with schizophrenia have the highest suicide risk and those aged 65 and older have the lowest. People with schizophrenia overall have a 4.5-fold increased risk of dying from suicide.
A study found that Vitamin B6 deficiency is associated with social deficits, cognitive impairment, and hyperactivated noradrenergic systems in mice. Supplementing the brain with Vitamin B6 improved these abnormalities, suggesting a potential therapeutic strategy for schizophrenia patients with Vitamin B6 deficiency.
Researchers discovered that mitochondrial dysfunction is linked to schizophrenia in patients with 22q11.2 deletion syndrome, who are 25 times more likely to develop the condition. Increased mitochondrial biogenesis is associated with the absence of schizophrenia.
A new study successfully treated flies displaying behavioral problems linked to schizophrenia-associated genes using common anti-psychotics. The research identified two key genes, Rim and CACNA1A/CACNA1B, which are involved in neurotransmitter release and electrical signaling in neurons.
Research finds that medications commonly prescribed for schizophrenia may worsen brain functioning, particularly among patients taking multiple psychotropic drugs. A study of 1,120 participants with schizophrenia found that 63% had an anticholinergic cognitive burden score of at least 3.
Researchers used genetic engineering tools to create a virus that can enter specific neurons and insert new genetic code, inducing modified protein production. In mice tests, the alteration was sufficient to modify brain activity, indicating potential biomarker for psychiatric disorders like schizophrenia and autism.
A new study from Aarhus University finds that almost half of parents with children to a parent with schizophrenia or bipolar disorder also meet the criteria for a mental disorder. This can impact family life and child development. The study suggests increased attention is needed for these families, with specialized efforts recommended.
A study by Penn researchers found that people with schizophrenia have a compromised blood-brain barrier, allowing the immune system to improperly influence the central nervous system. This inflammation contributes to the condition's symptoms. The findings may also apply to other mental disorders.
A simple dietary supplement betaine reduces behavioral symptoms in mice with a genetic mutation that causes schizophrenia. Betaine supplements likely protect proteins that build neurons' cellular skeletons, restoring healthy structures.
A new study published in Translational Psychiatry reveals that individuals with high genetic predisposition to schizophrenia are disproportionately affected by cannabis use, experiencing a 60% higher risk of psychotic experiences. Cannabis users, compared to non-users, have higher rates of psychotic experiences across the board.
A multinational study of nearly 200,000 people found significant sex-dependent differences in the genetics of schizophrenia, bipolar disorder, and major depressive disorders. The findings suggest that interactions between genes and sex may affect disease risk and progression.
A pilot study from North Carolina State University and the University of North Carolina at Chapel Hill found evidence of Bartonella infection in the blood of people with schizophrenia and schizoaffective disorder. The study suggests a potential link between Bartonella infection and neuropsychiatric disease, particularly schizophrenia.
Researchers found that people with schizophrenia, bipolar disorder, or major depression are more likely to die within 30 days and one year after a heart attack. The study highlights chronic health inequalities faced by those with serious mental illness and calls for urgent action to address disparities.
High-strength nicotine e-cigarettes have been found to be an effective smoking cessation method for adults with schizophrenia. In a 12-week study, 40 participants showed a sustained 50% reduction in smoking or complete abstinence, and significant improvements in blood pressure, heart rate, and quality of life.
Researchers identified somatic gene mutations in brain cells of people with schizophrenia that disrupted synaptic function and affected proteins critical for neural signaling. The study found that these rare mutations could contribute to the disease's neuropathology, particularly in genes associated with glutamate receptor function.
Researchers have determined the three-dimensional structure of glycine transporter GlyT1, providing insight into its regulation and potential inhibition. This discovery could lead to effective drugs that inhibit GlyT1 function, with major implications for treating schizophrenia and other mental disorders.
A comprehensive study combining 27 research studies and 10,000 participant data reveals strong associations between cardiovascular risk factors and cognitive impairment in individuals with schizophrenia. The findings suggest that managing cardiovascular conditions is essential to mitigate cognitive decline in these patients.
A new study by researchers at the University of Texas Health Science Center at Houston found that dropping out of high school, having schizophrenia, or a co-occurring personality disorder increases the likelihood of someone becoming a high utilizer. The research used machine learning to analyze deidentified electronic health record dat...
Researchers identified key risk genes associated with schizophrenia and their impact on antipsychotic medication efficacy. Examining these single nucleotide polymorphisms (SNPs) can help differentiate between responsive and treatment-resistant patients.
Scientists used X-ray technology to compare brain tissues of schizophrenia patients with those of healthy individuals, revealing unique structural differences. The findings suggest a link between these differences and the onset of the disease, paving the way for potential new treatments.
Researchers found that neuron structures differ between brain areas and individuals, with variations in shape and curvature affecting cognitive functions. The study used nanotomography to analyze brain tissue samples from 34 schizophrenia and 4 control cases.
Researchers found modest differences in gene expression between individuals with a mental disorder and those without, but more pronounced differences in transcript levels. The study identifies specific transcripts associated with each disorder, providing insights into their distinctness and potential treatment responses.
A significant link between placental gene-expression loci and neonatal brain volume was found, with stronger correlations in males than females. Early life complications may exacerbate the risk of neurodevelopmental illness in individuals with schizophrenia-associated genetic markers.
A genetic scoring study published in PNAS found that specific genes in the placenta can predict a baby's brain size at birth and its rate of cognitive development, which may lead to schizophrenia later in life. The study suggests that targeting placental health may reduce schizophrenia risk, particularly in males.
A recent observational study of 7,300 adults with COVID-19 found that individuals with a schizophrenia spectrum diagnosis had an increased risk of death, while mood and anxiety disorders were not associated with higher mortality rates. The study suggests that psychiatric disorders may be linked to poorer outcomes in patients with COVID-19
A new study finds that people with schizophrenia are almost three times more likely to die from COVID-19 than those without the mental disorder. The study, led by researchers at NYU Langone Health, shows that schizophrenia is the biggest risk factor for death after age, with a 2.7-fold increased odds of dying.
Researchers developed a machine learning tool to analyze brain scans and identify risk for earlier diagnosis and treatment. The tool accurately identified individuals with schizotypal personality traits at high risk of developing schizophrenia.
A new drug target for schizophrenia will be assessed using a technical approach developed by researchers from the University of Oxford and Earlham Institute. The goal is to identify proteins that may represent promising targets for treatment, which could lead to improved understanding and development of novel treatments.
A study conducted at the University of Turku found that patients with schizophrenia have an increased risk of developing Parkinson's disease. The research suggests that alterations in the brain's dopamine system may be a key factor contributing to this increased risk.
Researchers at UTHealth have discovered a gene signaling pathway linked to schizophrenia using human-induced pluripotent stem cells. The PI3K/GSK3 pathway was found to be dysregulated in neurons from patients with schizophrenia, with SGK1 inhibitor being associated with the condition.
Researchers from the University of Tsukuba found that low-intensity exercise during adolescence can significantly reduce abnormal behaviors in a mouse model of schizophrenia. The study suggests that mild exercise habits during development could have a powerful preventative effect in individuals genetically predisposed to schizophrenia.
A recent study has identified a genetic variation that influences cognition and IQ in people with schizophrenia, suggesting the possibility of developing new therapies to target learning and memory problems. Higher levels of a specific brain chemical were found to be associated with better visual and working memory.
Researchers found that combining long-acting antipsychotic medication with cognitive training led to significant improvements in cognitive deficits and work/school functioning in schizophrenia patients. The study, published in Psychological Medicine, suggests a potential breakthrough in treating the condition.
Researchers at Cornell Tech used smartphone data to predict episodes of schizophrenic relapse, analyzing movement, ambient sound and sleep patterns. The method found a median 108% increase in behavior anomalies before relapse.
A computer brain circuit has identified a potential mechanism for impaired decision making in schizophrenia, linked to reduced activity of molecules called NDMA receptors. The model's results provide new insight that may inform future treatments for neuropsychiatric conditions.
Researchers found that people with a genetic deletion syndrome are more excitable and experience abnormalities in calcium signaling, leading to an increased risk of developing schizophrenia. The study identified a single gene, DGCR8, as the main player in these cellular defects.